MX2008013760A - Compuestos restringidos como antagonistas del receptor del peptido relacionado con el gen de calcitonica (cgrp). - Google Patents
Compuestos restringidos como antagonistas del receptor del peptido relacionado con el gen de calcitonica (cgrp).Info
- Publication number
- MX2008013760A MX2008013760A MX2008013760A MX2008013760A MX2008013760A MX 2008013760 A MX2008013760 A MX 2008013760A MX 2008013760 A MX2008013760 A MX 2008013760A MX 2008013760 A MX2008013760 A MX 2008013760A MX 2008013760 A MX2008013760 A MX 2008013760A
- Authority
- MX
- Mexico
- Prior art keywords
- oxo
- mmol
- mixture
- chloro
- indazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 225
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract description 13
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title abstract description 11
- 229940044551 receptor antagonist Drugs 0.000 title abstract description 4
- 239000002464 receptor antagonist Substances 0.000 title abstract description 4
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 20
- 206010027599 migraine Diseases 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims description 558
- -1 N- (R9) -piperazinyl Chemical group 0.000 claims description 369
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 67
- 125000000217 alkyl group Chemical group 0.000 claims description 64
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 31
- 125000001475 halogen functional group Chemical group 0.000 claims description 27
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 21
- 125000001188 haloalkyl group Chemical group 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000006357 methylene carbonyl group Chemical group [H]C([H])([*:1])C([*:2])=O 0.000 claims description 5
- LUVYLURQXCSXOS-UHFFFAOYSA-N 4h-thieno[3,2-b]pyridin-5-one Chemical compound OC1=CC=C2SC=CC2=N1 LUVYLURQXCSXOS-UHFFFAOYSA-N 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- JDXAIRURQACNQA-SFHVURJKSA-N 2-chloro-6-[1-[2-[(7s)-4-chloro-9-(2,2-dimethylpropyl)-8-oxo-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]piperidin-4-yl]-4h-thieno[3,2-b]pyridin-5-one Chemical compound O=C([C@H](CC(=O)N1CCC(CC1)C=1C(NC=2C=C(Cl)SC=2C=1)=O)C1)N(CC(C)(C)C)CC2=C1C=C(Cl)C1=C2C=NN1 JDXAIRURQACNQA-SFHVURJKSA-N 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- CHOQMYCCGRMOTP-AWEZNQCLSA-N (7s)-1,4-dichloro-7-[2-oxo-2-[4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidin-1-yl]ethyl]-9-(2,2,2-trifluoroethyl)-2,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound O=C([C@H](CC(=O)N1CCC(CC1)N1C(NC2=NC=CC=C21)=O)C1)N(CC(F)(F)F)CC2=C1C=C(Cl)C1=NNC(Cl)=C21 CHOQMYCCGRMOTP-AWEZNQCLSA-N 0.000 claims description 2
- MHTPTFZHGFHECJ-AWEZNQCLSA-N (7s)-4-bromo-1-chloro-7-[2-oxo-2-[4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidin-1-yl]ethyl]-9-(2,2,2-trifluoroethyl)-2,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound O=C([C@H](CC(=O)N1CCC(CC1)N1C(NC2=NC=CC=C21)=O)C1)N(CC(F)(F)F)CC2=C1C=C(Br)C1=NNC(Cl)=C21 MHTPTFZHGFHECJ-AWEZNQCLSA-N 0.000 claims description 2
- KTGHSVZLFVDMGQ-SFHVURJKSA-N (7s)-4-chloro-7-[2-[4-[3-(2-fluorophenyl)-2-oxoimidazol-1-yl]piperidin-1-yl]-2-oxoethyl]-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound FC1=CC=CC=C1N1C(=O)N(C2CCN(CC2)C(=O)C[C@H]2C(N(CC(F)(F)F)CC3=C4C=NNC4=C(Cl)C=C3C2)=O)C=C1 KTGHSVZLFVDMGQ-SFHVURJKSA-N 0.000 claims description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 claims description 2
- YZCARBAUHDWSEA-SFHVURJKSA-N 2-bromo-6-[1-[2-[(7s)-4-chloro-9-(2,2-dimethylpropyl)-8-oxo-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]piperidin-4-yl]-4h-thieno[3,2-b]pyridin-5-one Chemical compound O=C([C@H](CC(=O)N1CCC(CC1)C=1C(NC=2C=C(Br)SC=2C=1)=O)C1)N(CC(C)(C)C)CC2=C1C=C(Cl)C1=C2C=NN1 YZCARBAUHDWSEA-SFHVURJKSA-N 0.000 claims description 2
- TZYVTSVREWREKC-SFHVURJKSA-N 3-chloro-6-[1-[2-[(7s)-4-chloro-9-(2,2-dimethylpropyl)-8-oxo-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]piperidin-4-yl]-4h-thieno[3,2-b]pyridin-5-one Chemical compound O=C([C@H](CC(=O)N1CCC(CC1)C=1C(NC=2C(Cl)=CSC=2C=1)=O)C1)N(CC(C)(C)C)CC2=C1C=C(Cl)C1=C2C=NN1 TZYVTSVREWREKC-SFHVURJKSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- AVRPHUJQACDXTJ-NRFANRHFSA-N (4s)-7-chloro-2-(2,2-dimethylpropyl)-4-[2-[4-(1-methyl-5-oxo-4h-pyrrolo[3,2-b]pyridin-6-yl)piperidin-1-yl]-2-oxoethyl]-1,4,5,8-tetrahydropyrrolo[2,3-i][2]benzazepin-3-one Chemical compound C1C2=CC(Cl)=C(NC=C3)C3=C2CN(CC(C)(C)C)C(=O)[C@@H]1CC(=O)N(CC1)CCC1C(C(=O)N1)=CC2=C1C=CN2C AVRPHUJQACDXTJ-NRFANRHFSA-N 0.000 claims 1
- FKYJBYRSUJTSRF-SFHVURJKSA-N (7s)-4-chloro-7-[2-[4-[3-(2-fluorophenyl)-2-oxoimidazolidin-1-yl]piperidin-1-yl]-2-oxoethyl]-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound FC1=CC=CC=C1N1C(=O)N(C2CCN(CC2)C(=O)C[C@H]2C(N(CC(F)(F)F)CC3=C4C=NNC4=C(Cl)C=C3C2)=O)CC1 FKYJBYRSUJTSRF-SFHVURJKSA-N 0.000 claims 1
- XBCYIRSPAKJFDL-UHFFFAOYSA-N 1-(2,2,2-trifluoroethyl)-6,7,9,10-tetrahydro-2H-pyrazolo[3,4-i][2]benzazepin-8-one Chemical compound FC(CC1=NNC=2C=CC3=C(C1=2)CNC(CC3)=O)(F)F XBCYIRSPAKJFDL-UHFFFAOYSA-N 0.000 claims 1
- HEJMMTPRNAEVRN-SFHVURJKSA-N 3-bromo-6-[1-[2-[(7s)-4-chloro-9-(2,2-dimethylpropyl)-8-oxo-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]piperidin-4-yl]-4h-thieno[3,2-b]pyridin-5-one Chemical compound O=C([C@H](CC(=O)N1CCC(CC1)C=1C(NC=2C(Br)=CSC=2C=1)=O)C1)N(CC(C)(C)C)CC2=C1C=C(Cl)C1=C2C=NN1 HEJMMTPRNAEVRN-SFHVURJKSA-N 0.000 claims 1
- WTVNFKVGGUWHQC-UHFFFAOYSA-N decane-2,4-dione Chemical compound CCCCCCC(=O)CC(C)=O WTVNFKVGGUWHQC-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 32
- 206010019233 Headaches Diseases 0.000 abstract description 13
- 231100000869 headache Toxicity 0.000 abstract description 9
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000008485 antagonism Effects 0.000 abstract description 4
- 208000006673 asthma Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 208000014674 injury Diseases 0.000 abstract description 4
- 230000009245 menopause Effects 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 230000024883 vasodilation Effects 0.000 abstract description 4
- 230000005796 circulatory shock Effects 0.000 abstract description 3
- 230000001272 neurogenic effect Effects 0.000 abstract description 3
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 363
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 327
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 256
- 238000006243 chemical reaction Methods 0.000 description 252
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 226
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 184
- 239000007787 solid Substances 0.000 description 183
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 168
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 156
- 235000019439 ethyl acetate Nutrition 0.000 description 128
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 120
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 114
- 239000000463 material Substances 0.000 description 112
- 238000005481 NMR spectroscopy Methods 0.000 description 100
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 100
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 96
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 96
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 93
- 239000000243 solution Substances 0.000 description 93
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 92
- 235000019341 magnesium sulphate Nutrition 0.000 description 92
- 239000002253 acid Substances 0.000 description 89
- 150000004702 methyl esters Chemical class 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 78
- 239000011541 reaction mixture Substances 0.000 description 77
- 235000017557 sodium bicarbonate Nutrition 0.000 description 77
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 72
- 239000002904 solvent Substances 0.000 description 72
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
- 239000008346 aqueous phase Substances 0.000 description 67
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 66
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 65
- 239000000047 product Substances 0.000 description 65
- 239000003921 oil Substances 0.000 description 61
- 235000019198 oils Nutrition 0.000 description 61
- 238000003756 stirring Methods 0.000 description 61
- 238000010992 reflux Methods 0.000 description 59
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 57
- 239000012267 brine Substances 0.000 description 56
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 56
- 239000012043 crude product Substances 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 49
- 101150041968 CDC13 gene Proteins 0.000 description 48
- 239000000741 silica gel Substances 0.000 description 46
- 229910002027 silica gel Inorganic materials 0.000 description 46
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 43
- 239000000706 filtrate Substances 0.000 description 39
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 38
- 238000004587 chromatography analysis Methods 0.000 description 37
- 238000002953 preparative HPLC Methods 0.000 description 36
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 35
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 34
- 229910000027 potassium carbonate Inorganic materials 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 239000012071 phase Substances 0.000 description 32
- 230000002441 reversible effect Effects 0.000 description 30
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 30
- 102100038518 Calcitonin Human genes 0.000 description 29
- 238000000746 purification Methods 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 26
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical class ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 25
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 24
- 229940022663 acetate Drugs 0.000 description 24
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 23
- 239000012044 organic layer Substances 0.000 description 23
- 229920006395 saturated elastomer Polymers 0.000 description 23
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 22
- 239000012317 TBTU Substances 0.000 description 21
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 21
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 19
- 239000010410 layer Substances 0.000 description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 18
- 238000001819 mass spectrum Methods 0.000 description 18
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 17
- 238000001239 high-resolution electron microscopy Methods 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 14
- GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- CDMSEVFXYQUTEW-QMMMGPOBSA-N 2-[(7s)-4-chloro-8-oxo-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1N(CC(F)(F)F)C(=O)[C@H](CC(=O)O)CC2=CC(Cl)=C(NN=C3)C3=C21 CDMSEVFXYQUTEW-QMMMGPOBSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 13
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 13
- 239000012230 colorless oil Substances 0.000 description 13
- 238000004949 mass spectrometry Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 239000006260 foam Substances 0.000 description 12
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 12
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 11
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 10
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 10
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 10
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 10
- 230000003197 catalytic effect Effects 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 10
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 9
- XDIAMRVROCPPBK-UHFFFAOYSA-N 2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)CN XDIAMRVROCPPBK-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 235000011056 potassium acetate Nutrition 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 7
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
- 235000017803 cinnamon Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 7
- 235000019345 sodium thiosulphate Nutrition 0.000 description 7
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical class CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 7
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 6
- 229910001873 dinitrogen Inorganic materials 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 6
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- UXJWASOYBZTNAI-UHFFFAOYSA-N 1H-azepin-4-ylcarbamic acid Chemical compound C1=CNC=CC(=C1)NC(=O)O UXJWASOYBZTNAI-UHFFFAOYSA-N 0.000 description 5
- PMPQNANYCFJYHI-QMMMGPOBSA-N 2-[(7s)-4-bromo-8-oxo-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1N(CC(F)(F)F)C(=O)[C@H](CC(=O)O)CC2=CC(Br)=C(NN=C3)C3=C21 PMPQNANYCFJYHI-QMMMGPOBSA-N 0.000 description 5
- USOSUQZREODCRK-UHFFFAOYSA-N 3-piperidin-4-yl-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound O=C1NC2=CC=CC=C2CCN1C1CCNCC1 USOSUQZREODCRK-UHFFFAOYSA-N 0.000 description 5
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 5
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- GIOMCKFZCZKAMD-QGZVFWFLSA-N (2R)-3-[4-(chloromethyl)-1H-indazol-5-yl]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@@H](C(=O)O)CC=1C(=C2C=NNC2=CC=1)CCl GIOMCKFZCZKAMD-QGZVFWFLSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- DVENHCKTCNZFFC-UHFFFAOYSA-N 6-piperidin-4-yl-4h-thieno[3,2-b]pyridin-5-one Chemical compound O=C1NC=2C=CSC=2C=C1C1CCNCC1 DVENHCKTCNZFFC-UHFFFAOYSA-N 0.000 description 4
- 102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XDFFYJGKULMBKM-UHFFFAOYSA-N azanium;acetonitrile;acetate;hydrate Chemical compound [NH4+].O.CC#N.CC([O-])=O XDFFYJGKULMBKM-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- OCFPEEXBJKVQQU-GOSISDBHSA-N methyl (2r)-3-[4-(chloromethyl)-1h-indazol-5-yl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound N([C@H](CC=1C(=C2C=NNC2=CC=1)CCl)C(=O)OC)C(=O)OCC1=CC=CC=C1 OCFPEEXBJKVQQU-GOSISDBHSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000001384 succinic acid Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- FQQNBFVWDZFQKH-UHFFFAOYSA-N (5-methoxy-1-methylpyrrolo[3,2-b]pyridin-6-yl)boronic acid Chemical compound C1=C(B(O)O)C(OC)=NC2=C1N(C)C=C2 FQQNBFVWDZFQKH-UHFFFAOYSA-N 0.000 description 3
- LQBYRDGFLYNEGM-UHFFFAOYSA-N (5-methoxy-1h-pyrrolo[3,2-b]pyridin-6-yl)boronic acid Chemical compound C1=C(B(O)O)C(OC)=NC2=C1NC=C2 LQBYRDGFLYNEGM-UHFFFAOYSA-N 0.000 description 3
- NBUOYVBSFOCTOF-UHFFFAOYSA-N (5-methoxypyrrolo[3,2-b]pyridin-1-yl)-tri(propan-2-yl)silane Chemical compound COC1=CC=C2N([Si](C(C)C)(C(C)C)C(C)C)C=CC2=N1 NBUOYVBSFOCTOF-UHFFFAOYSA-N 0.000 description 3
- NBRLRDAKWUNZIN-UHFFFAOYSA-N (6-chloropyrrolo[2,3-b]pyridin-1-yl)-tri(propan-2-yl)silane Chemical compound C1=C(Cl)N=C2N([Si](C(C)C)(C(C)C)C(C)C)C=CC2=C1 NBRLRDAKWUNZIN-UHFFFAOYSA-N 0.000 description 3
- MHAYHURNANUDHE-UHFFFAOYSA-N 2,2-dimethyl-n-thiophen-3-ylpropanamide Chemical compound CC(C)(C)C(=O)NC=1C=CSC=1 MHAYHURNANUDHE-UHFFFAOYSA-N 0.000 description 3
- JFVIFCFHKDLYLF-UHFFFAOYSA-N 3-[6-iodo-2-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]propanoic acid Chemical compound C(C)(C)(C)OC(=O)NC=1C(=C(CCC(=O)O)C(=CC=1)I)C JFVIFCFHKDLYLF-UHFFFAOYSA-N 0.000 description 3
- IDTTYANIUTZKHE-UHFFFAOYSA-N 3-bromo-6-piperidin-4-yl-4h-thieno[3,2-b]pyridin-5-one Chemical compound O=C1NC=2C(Br)=CSC=2C=C1C1CCNCC1 IDTTYANIUTZKHE-UHFFFAOYSA-N 0.000 description 3
- ADEKJVNFIQUGRR-UHFFFAOYSA-N 4h-pyridin-3-one Chemical compound O=C1CC=CN=C1 ADEKJVNFIQUGRR-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 206010003497 Asphyxia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102100030697 Receptor activity-modifying protein 1 Human genes 0.000 description 3
- BYKQIRVBKICOHH-UHFFFAOYSA-N [Rh+].C1=CC=CCCCC1.C1=CC=CC=C1 Chemical compound [Rh+].C1=CC=CCCCC1.C1=CC=CC=C1 BYKQIRVBKICOHH-UHFFFAOYSA-N 0.000 description 3
- GGISZLOBBISXOZ-UHFFFAOYSA-N acetic acid;chloroform Chemical compound CC(O)=O.ClC(Cl)Cl GGISZLOBBISXOZ-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- LJDDIYSQQHLCLN-OYKVQYDMSA-N diethyl (2s)-2-[2-acetyloxy-1-[3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethyl]butanedioate Chemical compound CCOC(=O)C[C@H](C(=O)OCC)C(COC(C)=O)C1=CC=C(NC(=O)OC(C)(C)C)C(C)=C1 LJDDIYSQQHLCLN-OYKVQYDMSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- VJHSCCBWGUKJBQ-JTQLQIEISA-N dimethyl (2s)-2-[[4-(hydroxymethyl)-1h-indazol-5-yl]methyl]butanedioate Chemical compound COC(=O)C[C@@H](C(=O)OC)CC1=CC=C2NN=CC2=C1CO VJHSCCBWGUKJBQ-JTQLQIEISA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000006178 methyl benzyl group Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 3
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- YBJBLZWJMQMPGF-GOSISDBHSA-N (2R)-3-[4-(acetyloxymethyl)-7-chloro-1H-indazol-5-yl]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C(C)(=O)OCC1=C2C=NNC2=C(C=C1C[C@H](C(=O)O)NC(=O)OCC1=CC=CC=C1)Cl YBJBLZWJMQMPGF-GOSISDBHSA-N 0.000 description 2
- AAZCFOYBTCRVEJ-HTQZYQBOSA-N (2R,5R)-2,5-diethylphospholane Chemical compound CC[C@@H]1CC[C@@H](CC)P1 AAZCFOYBTCRVEJ-HTQZYQBOSA-N 0.000 description 2
- ZBKIFLUMOTZCND-ZETCQYMHSA-N (2s)-2-[[7-bromo-4-(hydroxymethyl)-1h-indazol-5-yl]methyl]butanedioic acid Chemical compound OCC1=C(C[C@@H](CC(O)=O)C(O)=O)C=C(Br)C2=C1C=NN2 ZBKIFLUMOTZCND-ZETCQYMHSA-N 0.000 description 2
- TXSUNOURMQFQER-SECBINFHSA-N (3s)-3-[[4-(hydroxymethyl)-1h-indazol-5-yl]methyl]oxolan-2-one Chemical compound C1=CC=2NN=CC=2C(CO)=C1C[C@H]1CCOC1=O TXSUNOURMQFQER-SECBINFHSA-N 0.000 description 2
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 2
- ZWCRLWCTGOZNEP-SNVBAGLBSA-N (7r)-4-chloro-7-hydroxy-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound C1N(CC(F)(F)F)C(=O)[C@H](O)CC2=CC(Cl)=C(NN=C3)C3=C21 ZWCRLWCTGOZNEP-SNVBAGLBSA-N 0.000 description 2
- XFWNDGAMYOYSJA-CYBMUJFWSA-N (7r)-7-amino-9-(2,2-dimethylpropyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound C1[C@@H](N)C(=O)N(CC(C)(C)C)CC2=C1C=CC1=C2C=NN1 XFWNDGAMYOYSJA-CYBMUJFWSA-N 0.000 description 2
- XWQRSVFRTSVQAH-MRXNPFEDSA-N (7r)-7-amino-9-(2-piperidin-1-ylethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound C([C@H](C1=O)N)C2=CC=C3NN=CC3=C2CN1CCN1CCCCC1 XWQRSVFRTSVQAH-MRXNPFEDSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- LTOLEFMMYMSLPR-UHFFFAOYSA-N 1-benzyl-n-[2-(2-nitrophenyl)ethyl]piperidin-4-amine Chemical compound [O-][N+](=O)C1=CC=CC=C1CCNC1CCN(CC=2C=CC=CC=2)CC1 LTOLEFMMYMSLPR-UHFFFAOYSA-N 0.000 description 2
- ANLHHEIMCNZGLV-UHFFFAOYSA-N 1-phenyl-3-piperidin-4-ylimidazol-2-one;hydrochloride Chemical compound Cl.O=C1N(C2CCNCC2)C=CN1C1=CC=CC=C1 ANLHHEIMCNZGLV-UHFFFAOYSA-N 0.000 description 2
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- ZHQHUGDDYSPNTM-UHFFFAOYSA-N 2-(3-fluoro-2-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(F)=C1[N+]([O-])=O ZHQHUGDDYSPNTM-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- XPDQZRDRODSWAK-NSHDSACASA-N 2-[(7s)-4-bromo-9-(2,2-dimethylpropyl)-8-oxo-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1[C@@H](CC(O)=O)C(=O)N(CC(C)(C)C)CC2=C1C=C(Br)C1=C2C=NN1 XPDQZRDRODSWAK-NSHDSACASA-N 0.000 description 2
- VHGWIYHMXFPQMN-NSHDSACASA-N 2-[(7s)-4-ethyl-8-oxo-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1[C@@H](CC(O)=O)C(=O)N(CC(F)(F)F)CC2=C1C=C(CC)C1=C2C=NN1 VHGWIYHMXFPQMN-NSHDSACASA-N 0.000 description 2
- XDIDDILYVHUFCC-NSHDSACASA-N 2-[(7s)-8-oxo-4-prop-1-en-2-yl-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1[C@@H](CC(O)=O)C(=O)N(CC(F)(F)F)CC2=C1C=C(C(=C)C)C1=C2C=NN1 XDIDDILYVHUFCC-NSHDSACASA-N 0.000 description 2
- NFMICTOBQBVEOG-UHFFFAOYSA-N 2-chloro-6-piperidin-4-yl-4h-thieno[3,2-b]pyridin-5-one Chemical compound C=1C=2SC(Cl)=CC=2NC(=O)C=1C1CCNCC1 NFMICTOBQBVEOG-UHFFFAOYSA-N 0.000 description 2
- ANSJTRRYCNYUJD-UHFFFAOYSA-N 2-ethenyl-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1C=C ANSJTRRYCNYUJD-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- UJTUCYBYKAXMMJ-UHFFFAOYSA-N 2-oxo-3-piperidin-4-yl-1h-imidazole-5-carbonitrile;hydrochloride Chemical compound Cl.O=C1NC(C#N)=CN1C1CCNCC1 UJTUCYBYKAXMMJ-UHFFFAOYSA-N 0.000 description 2
- SYTRWWIHWDEIPI-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-9-fluoro-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound O=C1NC=2C(F)=CC=CC=2CCN1C(CC1)CCN1CC1=CC=CC=C1 SYTRWWIHWDEIPI-UHFFFAOYSA-N 0.000 description 2
- WZYSKVMEVNRNLB-UHFFFAOYSA-N 3-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]-2-oxo-1h-imidazole-5-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)NC(C(O)=O)=C1 WZYSKVMEVNRNLB-UHFFFAOYSA-N 0.000 description 2
- CWWPGYUYJZYURK-UHFFFAOYSA-N 3-chloro-6-piperidin-4-yl-4h-thieno[3,2-b]pyridin-5-one Chemical compound O=C1NC=2C(Cl)=CSC=2C=C1C1CCNCC1 CWWPGYUYJZYURK-UHFFFAOYSA-N 0.000 description 2
- ZWMTWCIWYCWUQV-UHFFFAOYSA-N 4-(6-chloro-1h-pyrrolo[2,3-b]pyridin-4-yl)piperidin-4-ol Chemical compound C=1C(Cl)=NC=2NC=CC=2C=1C1(O)CCNCC1 ZWMTWCIWYCWUQV-UHFFFAOYSA-N 0.000 description 2
- XGQQDTBAMLGWRZ-UHFFFAOYSA-N 4-iodo-2-methyl-3-nitroaniline Chemical compound CC1=C(N)C=CC(I)=C1[N+]([O-])=O XGQQDTBAMLGWRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 2
- OAANNRLYCHHWRZ-UHFFFAOYSA-N 5-chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile Chemical class N#CC1=CC(Cl)=CC=C1C1=CCNCC1 OAANNRLYCHHWRZ-UHFFFAOYSA-N 0.000 description 2
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 2
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- KAKSWNSKDTZXGB-UHFFFAOYSA-N C1N(CC(F)(F)F)C(=O)C(NC(=O)O)CC2=CC(Cl)=C(NN=C3)C3=C21 Chemical compound C1N(CC(F)(F)F)C(=O)C(NC(=O)O)CC2=CC(Cl)=C(NN=C3)C3=C21 KAKSWNSKDTZXGB-UHFFFAOYSA-N 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 101710118454 Calcitonin gene-related peptide type 1 receptor Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229940083963 Peptide antagonist Drugs 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 206010047141 Vasodilatation Diseases 0.000 description 2
- PXESGSDDIFQOFB-UHFFFAOYSA-N [5-methoxy-1-tri(propan-2-yl)silylpyrrolo[3,2-b]pyridin-6-yl]boronic acid Chemical compound C1=C(B(O)O)C(OC)=NC2=C1N([Si](C(C)C)(C(C)C)C(C)C)C=C2 PXESGSDDIFQOFB-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical class O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229940045348 brown mixture Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- LJDDIYSQQHLCLN-MRTLOADZSA-N diethyl (2r)-2-[2-acetyloxy-1-[3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethyl]butanedioate Chemical compound CCOC(=O)C[C@@H](C(=O)OCC)C(COC(C)=O)C1=CC=C(NC(=O)OC(C)(C)C)C(C)=C1 LJDDIYSQQHLCLN-MRTLOADZSA-N 0.000 description 2
- LCTYXZYFHQXOBE-CQSZACIVSA-N diethyl (2r)-2-[[4-(acetyloxymethyl)-1h-indazol-5-yl]methyl]butanedioate Chemical compound CCOC(=O)C[C@H](C(=O)OCC)CC1=CC=C2NN=CC2=C1COC(C)=O LCTYXZYFHQXOBE-CQSZACIVSA-N 0.000 description 2
- JIWICRYTLWZKHS-ZDUSSCGKSA-N diethyl (2s)-2-[[4-(acetyloxymethyl)-7-chloro-1h-indazol-5-yl]methyl]butanedioate Chemical compound CCOC(=O)C[C@@H](C(=O)OCC)CC1=CC(Cl)=C2NN=CC2=C1COC(C)=O JIWICRYTLWZKHS-ZDUSSCGKSA-N 0.000 description 2
- HGPFTGAPPHDHPF-UHFFFAOYSA-N diethyl 2-[2-acetyloxy-1-[3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethylidene]butanedioate Chemical compound CCOC(=O)CC(C(=O)OCC)=C(COC(C)=O)C1=CC=C(NC(=O)OC(C)(C)C)C(C)=C1 HGPFTGAPPHDHPF-UHFFFAOYSA-N 0.000 description 2
- ZEFVHSWKYCYFFL-UHFFFAOYSA-N diethyl 2-methylidenebutanedioate Chemical compound CCOC(=O)CC(=C)C(=O)OCC ZEFVHSWKYCYFFL-UHFFFAOYSA-N 0.000 description 2
- OGJCUSFTJIEQRF-UHFFFAOYSA-N dimethyl 2-(3-fluoro-2-nitrophenyl)propanedioate Chemical compound COC(=O)C(C(=O)OC)C1=CC=CC(F)=C1[N+]([O-])=O OGJCUSFTJIEQRF-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- SXXWEJVOYOMBEV-GMUIIQOCSA-N methyl (2r)-3-[4-(chloromethyl)-1h-indazol-5-yl]-2-(phenylmethoxycarbonylamino)propanoate;hydrochloride Chemical compound Cl.N([C@H](CC=1C(=C2C=NNC2=CC=1)CCl)C(=O)OC)C(=O)OCC1=CC=CC=C1 SXXWEJVOYOMBEV-GMUIIQOCSA-N 0.000 description 2
- ZEXZSCMJWQKYIB-QGZVFWFLSA-N methyl (2r)-3-[7-chloro-4-(chloromethyl)-1h-indazol-5-yl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound N([C@H](CC=1C(=C2C=NNC2=C(Cl)C=1)CCl)C(=O)OC)C(=O)OCC1=CC=CC=C1 ZEXZSCMJWQKYIB-QGZVFWFLSA-N 0.000 description 2
- HYMWXVZOYWBBJS-UHFFFAOYSA-N methyl 3-[4-acetamido-2-(acetyloxymethyl)-3,5-dimethylphenyl]-2-(phenylmethoxycarbonylamino)prop-2-enoate Chemical compound C=1C(C)=C(NC(C)=O)C(C)=C(COC(C)=O)C=1C=C(C(=O)OC)NC(=O)OCC1=CC=CC=C1 HYMWXVZOYWBBJS-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- KHCJQXVEDLDHKF-UHFFFAOYSA-N n-(2-formylthiophen-3-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC=1C=CSC=1C=O KHCJQXVEDLDHKF-UHFFFAOYSA-N 0.000 description 2
- CNYQVNWECNEWJI-UHFFFAOYSA-N n-[2-(2-aminophenyl)ethyl]-1-benzylpiperidin-4-amine Chemical compound NC1=CC=CC=C1CCNC1CCN(CC=2C=CC=CC=2)CC1 CNYQVNWECNEWJI-UHFFFAOYSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000004963 pathophysiological condition Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 2
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 2
- 230000004895 regional blood flow Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- QPILZZVXGUNELN-UHFFFAOYSA-M sodium;4-amino-5-hydroxynaphthalene-2,7-disulfonate;hydron Chemical compound [Na+].OS(=O)(=O)C1=CC(O)=C2C(N)=CC(S([O-])(=O)=O)=CC2=C1 QPILZZVXGUNELN-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000005250 spinal neuron Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- OXEKYXNGJRGPGG-UHFFFAOYSA-N tert-butyl 3-(acetyloxymethyl)-2-methyl-4-[(5-oxo-2h-furan-4-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=C(C)C(COC(=O)C)=C1CC1=CCOC1=O OXEKYXNGJRGPGG-UHFFFAOYSA-N 0.000 description 2
- BELDFCGNBPTQBO-UHFFFAOYSA-N tert-butyl 4-[2-(2-nitropyridin-3-yl)ethylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NCCC1=CC=CN=C1[N+]([O-])=O BELDFCGNBPTQBO-UHFFFAOYSA-N 0.000 description 2
- WOGYDSNKMAALKC-UHFFFAOYSA-N tert-butyl n-[5-(hydroxymethyl)-4-iodo-2-methylphenyl]carbamate Chemical compound CC1=CC(I)=C(CO)C=C1NC(=O)OC(C)(C)C WOGYDSNKMAALKC-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- WTVXIBRMWGUIMI-UHFFFAOYSA-N trifluoro($l^{1}-oxidanylsulfonyl)methane Chemical group [O]S(=O)(=O)C(F)(F)F WTVXIBRMWGUIMI-UHFFFAOYSA-N 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- CXSZODDHFZIYBY-UHFFFAOYSA-N (2-iodo-5-phenylmethoxyphenyl)methanol Chemical compound C1=C(I)C(CO)=CC(OCC=2C=CC=CC=2)=C1 CXSZODDHFZIYBY-UHFFFAOYSA-N 0.000 description 1
- LSXIZUNTWDMCSP-MLCCFXAWSA-N (2S)-2-[2-acetyloxy-1-[3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethyl]butanedioic acid Chemical compound C(C)(=O)OCC(C1=CC(=C(C=C1)NC(=O)OC(C)(C)C)C)[C@@H](C(=O)O)CC(=O)O LSXIZUNTWDMCSP-MLCCFXAWSA-N 0.000 description 1
- IKSZAFKDYMCKMM-NSHDSACASA-N (2S)-2-[[2-(acetyloxymethyl)-4-amino-3-methylphenyl]methyl]butanedioic acid Chemical compound C(C)(=O)OCC1=C(C[C@H](C(=O)O)CC(=O)O)C=CC(=C1C)N IKSZAFKDYMCKMM-NSHDSACASA-N 0.000 description 1
- CBXFQAXJCADTQL-JTQLQIEISA-N (2S)-2-[[2-(acetyloxymethyl)-4-amino-5-bromo-3-methylphenyl]methyl]butanedioic acid Chemical compound C(C)(=O)OCC1=C(C[C@H](C(=O)O)CC(=O)O)C=C(C(=C1C)N)Br CBXFQAXJCADTQL-JTQLQIEISA-N 0.000 description 1
- MCTVOSXXKRGCNX-JTQLQIEISA-N (2S)-2-[[2-(acetyloxymethyl)-4-amino-5-chloro-3-methylphenyl]methyl]butanedioic acid Chemical compound C(C)(=O)OCC1=C(C[C@H](C(=O)O)CC(=O)O)C=C(C(=C1C)N)Cl MCTVOSXXKRGCNX-JTQLQIEISA-N 0.000 description 1
- QIWFQAODZGEBBD-VIFPVBQESA-N (2S)-2-[[4-(acetyloxymethyl)-7-bromo-1H-indazol-5-yl]methyl]butanedioic acid Chemical compound C(C)(=O)OCC1=C2C=NNC2=C(C=C1C[C@H](C(=O)O)CC(=O)O)Br QIWFQAODZGEBBD-VIFPVBQESA-N 0.000 description 1
- VEAJSZQUEFPZOM-VIFPVBQESA-N (2S)-2-[[4-(chloromethyl)-7-methyl-1H-indazol-5-yl]methyl]butanedioic acid Chemical compound ClCC1=C2C=NNC2=C(C=C1C[C@H](C(=O)O)CC(=O)O)C VEAJSZQUEFPZOM-VIFPVBQESA-N 0.000 description 1
- UVYZMJMDIMWDNJ-UHFFFAOYSA-N (3-amino-2-methylphenyl)methanol Chemical compound CC1=C(N)C=CC=C1CO UVYZMJMDIMWDNJ-UHFFFAOYSA-N 0.000 description 1
- BCQKYGYTOHXGLL-UHFFFAOYSA-N (3-amino-4-methylphenyl)methanol Chemical compound CC1=CC=C(CO)C=C1N BCQKYGYTOHXGLL-UHFFFAOYSA-N 0.000 description 1
- WWNGBMDVYSNISP-UHFFFAOYSA-N (3-methoxy-3-oxoprop-1-en-2-yl) benzoate Chemical compound COC(=O)C(=C)OC(=O)C1=CC=CC=C1 WWNGBMDVYSNISP-UHFFFAOYSA-N 0.000 description 1
- AFKLSWIRJUJWKY-UHFFFAOYSA-N (3-phenylmethoxyphenyl)methanol Chemical compound OCC1=CC=CC(OCC=2C=CC=CC=2)=C1 AFKLSWIRJUJWKY-UHFFFAOYSA-N 0.000 description 1
- NLPJHEXNDOIYOH-SNVBAGLBSA-N (7r)-7-amino-4-chloro-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound C1N(CC(F)(F)F)C(=O)[C@H](N)CC2=CC(Cl)=C(NN=C3)C3=C21 NLPJHEXNDOIYOH-SNVBAGLBSA-N 0.000 description 1
- NYSGFQBNMXCTNT-OAHLLOKOSA-N (7r)-7-amino-9-(2-pyrrolidin-1-ylethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound C([C@H](C1=O)N)C2=CC=C3NN=CC3=C2CN1CCN1CCCC1 NYSGFQBNMXCTNT-OAHLLOKOSA-N 0.000 description 1
- XLRWRBBUBQSBPG-CYBMUJFWSA-N (7r)-7-amino-9-[2-(dimethylamino)ethyl]-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound C1[C@@H](N)C(=O)N(CCN(C)C)CC2=C1C=CC1=C2C=NN1 XLRWRBBUBQSBPG-CYBMUJFWSA-N 0.000 description 1
- VBPMPNJTNKRJJE-AWEZNQCLSA-N (7s)-4-chloro-7-[2-oxo-2-[4-(2-oxo-1h-imidazol-3-yl)piperidin-1-yl]ethyl]-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound C([C@@H]1CC2=C(C=3C=NNC=3C(Cl)=C2)CN(C1=O)CC(F)(F)F)C(=O)N(CC1)CCC1N1C=CNC1=O VBPMPNJTNKRJJE-AWEZNQCLSA-N 0.000 description 1
- UQWXGLUCMNJCLM-HNNXBMFYSA-N (7s)-4-chloro-7-[2-oxo-2-[4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidin-1-yl]ethyl]-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound O=C([C@H](CC(=O)N1CCC(CC1)N1C(NC2=NC=CC=C21)=O)C1)N(CC(F)(F)F)CC2=C1C=C(Cl)C1=C2C=NN1 UQWXGLUCMNJCLM-HNNXBMFYSA-N 0.000 description 1
- DVJPIPGZNPEWIX-CYBMUJFWSA-N (7s)-9-(2,2-dimethylpropyl)-7-(2-hydroxyethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-8-one Chemical compound C1[C@@H](CCO)C(=O)N(CC(C)(C)C)CC2=C1C=CC1=C2C=NN1 DVJPIPGZNPEWIX-CYBMUJFWSA-N 0.000 description 1
- DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- SSNCMIDZGFCTST-UHFFFAOYSA-N 1,3-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1F SSNCMIDZGFCTST-UHFFFAOYSA-N 0.000 description 1
- UFFNNHYFJAVGTB-UHFFFAOYSA-N 1,3-dihydroimidazol-2-one;hydrochloride Chemical compound Cl.O=C1NC=CN1 UFFNNHYFJAVGTB-UHFFFAOYSA-N 0.000 description 1
- SJLIPOVZERLCNL-UHFFFAOYSA-N 1-(2-bromoethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CCBr SJLIPOVZERLCNL-UHFFFAOYSA-N 0.000 description 1
- NSHZQGGNPXEZFC-UHFFFAOYSA-N 1-(2-hydroxyethyl)-2,6-dimethylpyridine-4-thione Chemical compound CC1=CC(=S)C=C(C)N1CCO NSHZQGGNPXEZFC-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- NZVZVGPYTICZBZ-UHFFFAOYSA-N 1-benzylpiperidine Chemical compound C=1C=CC=CC=1CN1CCCCC1 NZVZVGPYTICZBZ-UHFFFAOYSA-N 0.000 description 1
- AMCXCJRGBUPXJZ-UHFFFAOYSA-N 1-methyl-6-piperidin-4-yl-4h-pyrrolo[3,2-b]pyridin-5-one Chemical compound C=1C=2N(C)C=CC=2NC(=O)C=1C1CCNCC1 AMCXCJRGBUPXJZ-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- JXSDCQISTUGLTB-UHFFFAOYSA-N 1H-indazol-7-ylcarbamic acid Chemical compound C1=CC2=C(C(=C1)NC(=O)O)NN=C2 JXSDCQISTUGLTB-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YYFVUVRJSGRIID-UHFFFAOYSA-N 1h-indazol-6-ylcarbamic acid Chemical compound OC(=O)NC1=CC=C2C=NNC2=C1 YYFVUVRJSGRIID-UHFFFAOYSA-N 0.000 description 1
- VHPDBNRXHUSCFP-UHFFFAOYSA-N 2-(4-amino-3-methyl-2-nitrophenyl)-1,3-dioxepane-4,7-dione Chemical compound C1(CCC(=O)OC(C2=C(C(=C(C=C2)N)C)[N+](=O)[O-])O1)=O VHPDBNRXHUSCFP-UHFFFAOYSA-N 0.000 description 1
- DKJWFKDJXPEAGS-GFCCVEGCSA-N 2-[(7r)-9-(2,2-dimethylpropyl)-8-oxo-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1[C@H](CC(O)=O)C(=O)N(CC(C)(C)C)CC2=C1C=CC1=C2C=NN1 DKJWFKDJXPEAGS-GFCCVEGCSA-N 0.000 description 1
- ZJOABMGBRJYBCM-ZETCQYMHSA-N 2-[(7s)-4-bromo-8-oxo-3,6,7,10-tetrahydrooxepino[3,4-e]indazol-7-yl]acetic acid Chemical compound C1OC(=O)[C@H](CC(=O)O)CC2=CC(Br)=C(NN=C3)C3=C21 ZJOABMGBRJYBCM-ZETCQYMHSA-N 0.000 description 1
- RURYFXDQSTWYLV-NSHDSACASA-N 2-[(7s)-4-chloro-9-(2,2-dimethylpropyl)-8-oxo-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1[C@@H](CC(O)=O)C(=O)N(CC(C)(C)C)CC2=C1C=C(Cl)C1=C2C=NN1 RURYFXDQSTWYLV-NSHDSACASA-N 0.000 description 1
- YXWDLCUXCNKLON-NSHDSACASA-N 2-[(7s)-8-oxo-4-propan-2-yl-9-(2,2,2-trifluoroethyl)-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1[C@@H](CC(O)=O)C(=O)N(CC(F)(F)F)CC2=C1C=C(C(C)C)C1=C2C=NN1 YXWDLCUXCNKLON-NSHDSACASA-N 0.000 description 1
- OFGXCOZNODYHEQ-OAHLLOKOSA-N 2-[(7s)-9-(2,2-dimethylpropyl)-8-oxo-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]ethyl acetate Chemical compound C1N(CC(C)(C)C)C(=O)[C@H](CCOC(=O)C)CC2=CC=C(NN=C3)C3=C21 OFGXCOZNODYHEQ-OAHLLOKOSA-N 0.000 description 1
- RXMKANXXNFSGRZ-AWEZNQCLSA-N 2-[(7s)-9-(2,2-dimethylpropyl)-8-oxo-4-propan-2-yl-3,6,7,10-tetrahydropyrazolo[3,4-i][2]benzazepin-7-yl]acetic acid Chemical compound C1[C@@H](CC(O)=O)C(=O)N(CC(C)(C)C)CC2=C1C=C(C(C)C)C1=C2C=NN1 RXMKANXXNFSGRZ-AWEZNQCLSA-N 0.000 description 1
- DZJKWSGTMLVFJA-UHFFFAOYSA-N 2-[1-(2,2-dimethylpropyl)-2-oxo-4,7-dihydro-3h-pyrazolo[3,4-h]quinolin-3-yl]acetic acid Chemical compound C1=C2NN=CC2=C2N(CC(C)(C)C)C(=O)C(CC(O)=O)CC2=C1 DZJKWSGTMLVFJA-UHFFFAOYSA-N 0.000 description 1
- RWSFZKWMVWPDGZ-UHFFFAOYSA-N 2-amino-6-fluorobenzoic acid Chemical compound NC1=CC=CC(F)=C1C(O)=O RWSFZKWMVWPDGZ-UHFFFAOYSA-N 0.000 description 1
- NMXHOLHJCGKMIM-UHFFFAOYSA-N 2-bromo-6-piperidin-4-yl-4h-thieno[3,2-b]pyridin-5-one Chemical compound C=1C=2SC(Br)=CC=2NC(=O)C=1C1CCNCC1 NMXHOLHJCGKMIM-UHFFFAOYSA-N 0.000 description 1
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BWZDDDSWGATMHF-UHFFFAOYSA-N 2-fluoro-6-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]amino]benzoic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=CC(F)=C1C(O)=O BWZDDDSWGATMHF-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- HFCFJYRLBAANKN-UHFFFAOYSA-N 2-methyl-3-nitroaniline Chemical compound CC1=C(N)C=CC=C1[N+]([O-])=O HFCFJYRLBAANKN-UHFFFAOYSA-N 0.000 description 1
- CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 1
- GPWHFPWZAPOYNO-UHFFFAOYSA-N 3,3-dimethylbutan-1-amine Chemical compound CC(C)(C)CCN GPWHFPWZAPOYNO-UHFFFAOYSA-N 0.000 description 1
- NVOIRTLNHGFSAA-UHFFFAOYSA-N 3-[2-(acetyloxymethyl)-3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-2-(phenylmethoxycarbonylamino)prop-2-enoic acid Chemical compound CC(=O)OCC1=C(C)C(NC(=O)OC(C)(C)C)=CC=C1C=C(C(O)=O)NC(=O)OCC1=CC=CC=C1 NVOIRTLNHGFSAA-UHFFFAOYSA-N 0.000 description 1
- WFNISJZUJCKTLT-UHFFFAOYSA-N 3-bromo-2-nitropyridine Chemical compound [O-][N+](=O)C1=NC=CC=C1Br WFNISJZUJCKTLT-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BRQJTDURZKRGHM-UHFFFAOYSA-N 3-ethenyl-2-nitropyridine Chemical compound [O-][N+](=O)C1=NC=CC=C1C=C BRQJTDURZKRGHM-UHFFFAOYSA-N 0.000 description 1
- BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 1
- MWBCICNNADRJTA-UHFFFAOYSA-N 3-piperidin-4-yl-1h-imidazol-2-one;hydrochloride Chemical compound Cl.O=C1NC=CN1C1CCNCC1 MWBCICNNADRJTA-UHFFFAOYSA-N 0.000 description 1
- XSGRXAKVRBGUCQ-UHFFFAOYSA-N 3-tert-butyl-2-oxopiperidine-1-carboxylic acid Chemical compound C(C)(C)(C)C1C(N(CCC1)C(=O)O)=O XSGRXAKVRBGUCQ-UHFFFAOYSA-N 0.000 description 1
- FPGGLMIYNLQOID-UHFFFAOYSA-N 3h-pyridin-2-one Chemical compound O=C1CC=CC=N1 FPGGLMIYNLQOID-UHFFFAOYSA-N 0.000 description 1
- SJISCEAZUHNOMD-UHFFFAOYSA-N 4-phenylcyclohexan-1-amine Chemical compound C1CC(N)CCC1C1=CC=CC=C1 SJISCEAZUHNOMD-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SKMJOYUGRCIODX-UHFFFAOYSA-N 5-chloro-2-(2,3-dihydropyridin-4-yl)benzonitrile;hydrochloride Chemical compound Cl.N#CC1=CC(Cl)=CC=C1C1=CC=NCC1 SKMJOYUGRCIODX-UHFFFAOYSA-N 0.000 description 1
- WTIFEVSWZUSXQL-UHFFFAOYSA-N 5-methoxy-1h-pyrrolo[3,2-b]pyridine Chemical compound COC1=CC=C2NC=CC2=N1 WTIFEVSWZUSXQL-UHFFFAOYSA-N 0.000 description 1
- YFSWMEULGSJYQO-FQEVSTJZSA-N 6-[1-[2-[(4s)-7-chloro-2-(2,2-dimethylpropyl)-3-oxo-1,4,5,8-tetrahydropyrrolo[2,3-i][2]benzazepin-4-yl]acetyl]piperidin-4-yl]-4h-thieno[3,2-b]pyridin-5-one Chemical compound O=C([C@H](CC(=O)N1CCC(CC1)C=1C(NC=2C=CSC=2C=1)=O)C1)N(CC(C)(C)C)CC2=C1C=C(Cl)C1=C2C=CN1 YFSWMEULGSJYQO-FQEVSTJZSA-N 0.000 description 1
- DSCOSIUAQUDGJM-UHFFFAOYSA-N 6-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=C2C=CNC2=N1 DSCOSIUAQUDGJM-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- CSFDUSRYIIZWRR-UHFFFAOYSA-N 7-fluoro-3-piperidin-4-yl-1h-benzimidazol-2-one;hydrochloride Chemical compound Cl.O=C1NC=2C(F)=CC=CC=2N1C1CCNCC1 CSFDUSRYIIZWRR-UHFFFAOYSA-N 0.000 description 1
- 101150067539 AMBP gene Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MSJQIBMGWPDGKQ-LBPRGKRZSA-N C(C)(=O)OCC1=C(C[C@H](C(=O)O)CC(=O)O)C=C(C(=C1C)N)C Chemical compound C(C)(=O)OCC1=C(C[C@H](C(=O)O)CC(=O)O)C=C(C(=C1C)N)C MSJQIBMGWPDGKQ-LBPRGKRZSA-N 0.000 description 1
- SIXCFZWMVWJLIZ-UHFFFAOYSA-N CC(C)[Si](C(C)C)(C(C)C)N(C=CC1=N2)C1=CC(C(CC1)=CCN1C(O)=O)=C2OC Chemical compound CC(C)[Si](C(C)C)(C(C)C)N(C=CC1=N2)C1=CC(C(CC1)=CCN1C(O)=O)=C2OC SIXCFZWMVWJLIZ-UHFFFAOYSA-N 0.000 description 1
- 229940127597 CGRP antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CJDSGWOUJVEOMX-VEIFNGETSA-N Cl.C(C1=CC=CC=C1)OC(=O)N[C@@H](C(=O)O)CC1=C(C(=C(C=C1)NC(=O)OC(C)(C)C)C)CO Chemical compound Cl.C(C1=CC=CC=C1)OC(=O)N[C@@H](C(=O)O)CC1=C(C(=C(C=C1)NC(=O)OC(C)(C)C)C)CO CJDSGWOUJVEOMX-VEIFNGETSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- TXDUTHBFYKGSAH-SFHVURJKSA-N Evodiamine Chemical compound C1=CC=C2N(C)[C@@H]3C(NC=4C5=CC=CC=4)=C5CCN3C(=O)C2=C1 TXDUTHBFYKGSAH-SFHVURJKSA-N 0.000 description 1
- HMXRXBIGGYUEAX-SFHVURJKSA-N Evodiamine Natural products CN1[C@H]2N(CCc3[nH]c4ccccc4c23)C(=O)c5ccccc15 HMXRXBIGGYUEAX-SFHVURJKSA-N 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 235000000533 Rosa gallica Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WKFOTPNKVANMMO-LJQANCHMSA-N [(2r)-3-[2-(acetyloxymethyl)-4-amino-3-methylphenyl]-1-methoxy-1-oxopropan-2-yl] benzoate Chemical compound C([C@H](C(=O)OC)OC(=O)C=1C=CC=CC=1)C1=CC=C(N)C(C)=C1COC(C)=O WKFOTPNKVANMMO-LJQANCHMSA-N 0.000 description 1
- PRDBLLIPPDOICK-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1 PRDBLLIPPDOICK-UHFFFAOYSA-N 0.000 description 1
- LGCZKWUOVYKCKK-UHFFFAOYSA-N [6-iodo-2-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]methyl acetate Chemical compound CC(=O)OCC1=C(I)C=CC(NC(=O)OC(C)(C)C)=C1C LGCZKWUOVYKCKK-UHFFFAOYSA-N 0.000 description 1
- CUZGMJRJJFTHCS-UHFFFAOYSA-M [Rh+].[O-]S(=O)(=O)C(F)(F)F Chemical compound [Rh+].[O-]S(=O)(=O)C(F)(F)F CUZGMJRJJFTHCS-UHFFFAOYSA-M 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- GSLDEZOOOSBFGP-UHFFFAOYSA-N alpha-methylene gamma-butyrolactone Chemical compound C=C1CCOC1=O GSLDEZOOOSBFGP-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000001503 aryl iodides Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 101150052500 cic-1 gene Proteins 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RXBQVRWXGHALRZ-XYOKQWHBSA-N diethyl (2e)-2-[(4-amino-3-methyl-2-nitrophenyl)methylidene]butanedioate Chemical compound CCOC(=O)C\C(C(=O)OCC)=C/C1=CC=C(N)C(C)=C1[N+]([O-])=O RXBQVRWXGHALRZ-XYOKQWHBSA-N 0.000 description 1
- ZDBPLOJGFZJKTJ-OAHLLOKOSA-N diethyl (2r)-2-[[2-(acetyloxymethyl)-4-amino-3-methylphenyl]methyl]butanedioate Chemical compound CCOC(=O)C[C@H](C(=O)OCC)CC1=CC=C(N)C(C)=C1COC(C)=O ZDBPLOJGFZJKTJ-OAHLLOKOSA-N 0.000 description 1
- ZDBPLOJGFZJKTJ-HNNXBMFYSA-N diethyl (2s)-2-[[2-(acetyloxymethyl)-4-amino-3-methylphenyl]methyl]butanedioate Chemical compound CCOC(=O)C[C@@H](C(=O)OCC)CC1=CC=C(N)C(C)=C1COC(C)=O ZDBPLOJGFZJKTJ-HNNXBMFYSA-N 0.000 description 1
- NFCUYSFILTXWHL-AWEZNQCLSA-N diethyl (2s)-2-[[2-(acetyloxymethyl)-4-amino-5-chloro-3-methylphenyl]methyl]butanedioate Chemical compound CCOC(=O)C[C@@H](C(=O)OCC)CC1=CC(Cl)=C(N)C(C)=C1COC(C)=O NFCUYSFILTXWHL-AWEZNQCLSA-N 0.000 description 1
- LCTYXZYFHQXOBE-AWEZNQCLSA-N diethyl (2s)-2-[[4-(acetyloxymethyl)-1h-indazol-5-yl]methyl]butanedioate Chemical compound CCOC(=O)C[C@@H](C(=O)OCC)CC1=CC=C2NN=CC2=C1COC(C)=O LCTYXZYFHQXOBE-AWEZNQCLSA-N 0.000 description 1
- WDBVVEVKMSONLU-HNNXBMFYSA-N diethyl (2s)-2-[[4-(acetyloxymethyl)-7-methyl-1h-indazol-5-yl]methyl]butanedioate Chemical compound CCOC(=O)C[C@@H](C(=O)OCC)CC1=CC(C)=C2NN=CC2=C1COC(C)=O WDBVVEVKMSONLU-HNNXBMFYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- VJHSCCBWGUKJBQ-SNVBAGLBSA-N dimethyl (2r)-2-[[4-(hydroxymethyl)-1h-indazol-5-yl]methyl]butanedioate Chemical compound COC(=O)C[C@H](C(=O)OC)CC1=CC=C2NN=CC2=C1CO VJHSCCBWGUKJBQ-SNVBAGLBSA-N 0.000 description 1
- ICSVHLLZUDKUSA-PPHPATTJSA-N dimethyl (2s)-2-[[4-(chloromethyl)-1h-indazol-5-yl]methyl]butanedioate;hydrochloride Chemical compound Cl.COC(=O)C[C@@H](C(=O)OC)CC1=CC=C2NN=CC2=C1CCl ICSVHLLZUDKUSA-PPHPATTJSA-N 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000011982 enantioselective catalyst Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- LRUJOFUURXUABL-UHFFFAOYSA-N ethyl 2-amino-3,3-diethoxypropanoate Chemical compound CCOC(OCC)C(N)C(=O)OCC LRUJOFUURXUABL-UHFFFAOYSA-N 0.000 description 1
- FTKASJMIPSSXBP-UHFFFAOYSA-N ethyl 2-nitroacetate Chemical compound CCOC(=O)C[N+]([O-])=O FTKASJMIPSSXBP-UHFFFAOYSA-N 0.000 description 1
- TVIGDTGNGQHJJI-UHFFFAOYSA-N ethyl 3,3-diethoxy-2-nitropropanoate Chemical compound CCOC(OCC)C([N+]([O-])=O)C(=O)OCC TVIGDTGNGQHJJI-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- KPFKISFXMZLWSI-HSZRJFAPSA-N methyl (2r)-3-[2-(acetyloxymethyl)-3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C([C@H](C(=O)OC)NC(=O)OCC=1C=CC=CC=1)C1=CC=C(NC(=O)OC(C)(C)C)C(C)=C1COC(C)=O KPFKISFXMZLWSI-HSZRJFAPSA-N 0.000 description 1
- SQXSEDLWRFYTJZ-LJQANCHMSA-N methyl (2r)-3-[2-(acetyloxymethyl)-4-amino-5-chloro-3-methylphenyl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C([C@H](C(=O)OC)NC(=O)OCC=1C=CC=CC=1)C1=CC(Cl)=C(N)C(C)=C1COC(C)=O SQXSEDLWRFYTJZ-LJQANCHMSA-N 0.000 description 1
- LHHQTEBKGWFQBV-OAQYLSRUSA-N methyl (2r)-3-[2-(hydroxymethyl)-3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C([C@H](C(=O)OC)NC(=O)OCC=1C=CC=CC=1)C1=CC=C(NC(=O)OC(C)(C)C)C(C)=C1CO LHHQTEBKGWFQBV-OAQYLSRUSA-N 0.000 description 1
- ZTJSRQDMMSSEPT-HXUWFJFHSA-N methyl (2r)-3-[4-(acetyloxymethyl)-1h-indazol-5-yl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound N([C@H](CC=1C(=C2C=NNC2=CC=1)COC(C)=O)C(=O)OC)C(=O)OCC1=CC=CC=C1 ZTJSRQDMMSSEPT-HXUWFJFHSA-N 0.000 description 1
- PNEDTZUWNNMCAO-QGZVFWFLSA-N methyl (2r)-3-[7-chloro-4-(hydroxymethyl)-1h-indazol-5-yl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound N([C@H](CC=1C(=C2C=NNC2=C(Cl)C=1)CO)C(=O)OC)C(=O)OCC1=CC=CC=C1 PNEDTZUWNNMCAO-QGZVFWFLSA-N 0.000 description 1
- STFUIEDYPRMRNN-UHFFFAOYSA-N methyl 2-(phenylmethoxycarbonylamino)prop-2-enoate Chemical compound COC(=O)C(=C)NC(=O)OCC1=CC=CC=C1 STFUIEDYPRMRNN-UHFFFAOYSA-N 0.000 description 1
- OZZPXUDOSXJZNE-UHFFFAOYSA-N methyl 3-[2-(acetyloxymethyl)-3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-2-(phenylmethoxycarbonylamino)prop-2-enoate Chemical compound C=1C=C(NC(=O)OC(C)(C)C)C(C)=C(COC(C)=O)C=1C=C(C(=O)OC)NC(=O)OCC1=CC=CC=C1 OZZPXUDOSXJZNE-UHFFFAOYSA-N 0.000 description 1
- MRWRSTHVSJHZGK-UHFFFAOYSA-N methyl 3-[2-(acetyloxymethyl)-4-phenylmethoxyphenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]prop-2-enoate Chemical compound C1=C(COC(C)=O)C(C=C(NC(=O)OC(C)(C)C)C(=O)OC)=CC=C1OCC1=CC=CC=C1 MRWRSTHVSJHZGK-UHFFFAOYSA-N 0.000 description 1
- GDIMPLXZECZDDA-UHFFFAOYSA-N methyl 3-[2-(acetyloxymethyl)-4-phenylmethoxyphenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound C1=C(COC(C)=O)C(CC(C(=O)OC)NC(=O)OC(C)(C)C)=CC=C1OCC1=CC=CC=C1 GDIMPLXZECZDDA-UHFFFAOYSA-N 0.000 description 1
- KYUAIKDCVWXOGE-UHFFFAOYSA-N methyl 3-[2-(acetyloxymethyl)-5-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-2-(phenylmethoxycarbonylamino)prop-2-enoate Chemical compound C=1C(C)=C(NC(=O)OC(C)(C)C)C=C(COC(C)=O)C=1C=C(C(=O)OC)NC(=O)OCC1=CC=CC=C1 KYUAIKDCVWXOGE-UHFFFAOYSA-N 0.000 description 1
- ZTJSRQDMMSSEPT-UHFFFAOYSA-N methyl 3-[4-(acetyloxymethyl)-1h-indazol-5-yl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C=1C=C2NN=CC2=C(COC(C)=O)C=1CC(C(=O)OC)NC(=O)OCC1=CC=CC=C1 ZTJSRQDMMSSEPT-UHFFFAOYSA-N 0.000 description 1
- VRUKVNKYXZIDLI-UHFFFAOYSA-N methyl 3-[4-acetamido-2-(acetyloxymethyl)-3,5-dimethylphenyl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C=1C=CC=CC=1COC(=O)NC(C(=O)OC)CC1=CC(C)=C(NC(C)=O)C(C)=C1COC(C)=O VRUKVNKYXZIDLI-UHFFFAOYSA-N 0.000 description 1
- TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical compound CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 1
- SHSWVNSGEPSNKO-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-2-(3-fluoro-2-nitrophenyl)acetamide Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1CC(=O)NC1CCN(CC=2C=CC=CC=2)CC1 SHSWVNSGEPSNKO-UHFFFAOYSA-N 0.000 description 1
- MXVUKXAMXQZAAA-UHFFFAOYSA-N n-[2-(2-amino-3-fluorophenyl)ethyl]-1-benzylpiperidin-4-amine Chemical compound NC1=C(F)C=CC=C1CCNC1CCN(CC=2C=CC=CC=2)CC1 MXVUKXAMXQZAAA-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RAIYODFGMLZUDF-UHFFFAOYSA-N piperidin-1-ium;acetate Chemical compound CC([O-])=O.C1CC[NH2+]CC1 RAIYODFGMLZUDF-UHFFFAOYSA-N 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- CFLDCJYCZAHJCK-UHFFFAOYSA-N spiro[1,3-dihydroquinazoline-4,4'-piperidine]-2-one Chemical compound N1C(=O)NC2=CC=CC=C2C21CCNCC2 CFLDCJYCZAHJCK-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- MKQVGJJTCKZYOD-OAHLLOKOSA-N tert-butyl 3-(acetyloxymethyl)-2-methyl-4-[[(3s)-2-oxooxolan-3-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=C(C)C(COC(=O)C)=C1C[C@@H]1C(=O)OCC1 MKQVGJJTCKZYOD-OAHLLOKOSA-N 0.000 description 1
- UEXIKULFPYHJKF-UHFFFAOYSA-N tert-butyl 4-(2,2-dimethoxyethylamino)piperidine-1-carboxylate Chemical compound COC(OC)CNC1CCN(C(=O)OC(C)(C)C)CC1 UEXIKULFPYHJKF-UHFFFAOYSA-N 0.000 description 1
- IDGXMFMWNDFRKE-UHFFFAOYSA-N tert-butyl 4-(2,2-dimethoxyethylcarbamoylamino)piperidine-1-carboxylate Chemical compound COC(OC)CNC(=O)NC1CCN(C(=O)OC(C)(C)C)CC1 IDGXMFMWNDFRKE-UHFFFAOYSA-N 0.000 description 1
- ADFSCQGCEAKLOE-UHFFFAOYSA-N tert-butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate Chemical compound COC(=O)CC1CCN(C(=O)OC(C)(C)C)CC1 ADFSCQGCEAKLOE-UHFFFAOYSA-N 0.000 description 1
- IIGBENFKIOPRFC-UHFFFAOYSA-N tert-butyl 4-(2-oxo-3-phenylimidazol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)N(C=2C=CC=CC=2)C=C1 IIGBENFKIOPRFC-UHFFFAOYSA-N 0.000 description 1
- UEYCLJSSTRYKOH-UHFFFAOYSA-N tert-butyl 4-(2-oxo-4,5-dihydro-1h-pyrido[2,3-d][1,3]diazepin-3-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)NC2=NC=CC=C2CC1 UEYCLJSSTRYKOH-UHFFFAOYSA-N 0.000 description 1
- MFUSVNJAETWBDR-UHFFFAOYSA-N tert-butyl 4-(2-oxo-4,5-dihydro-1h-pyrido[3,2-d][1,3]diazepin-3-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)NC2=CC=CN=C2CC1 MFUSVNJAETWBDR-UHFFFAOYSA-N 0.000 description 1
- BGQUZUSCTWGIIO-UHFFFAOYSA-N tert-butyl 4-[2,2-dimethoxyethyl-[(2-fluorophenyl)carbamoyl]amino]piperidine-1-carboxylate Chemical compound C=1C=CC=C(F)C=1NC(=O)N(CC(OC)OC)C1CCN(C(=O)OC(C)(C)C)CC1 BGQUZUSCTWGIIO-UHFFFAOYSA-N 0.000 description 1
- JTOYMRROBPBLNQ-UHFFFAOYSA-N tert-butyl 4-[2-(3-nitropyridin-2-yl)ethylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NCCC1=NC=CC=C1[N+]([O-])=O JTOYMRROBPBLNQ-UHFFFAOYSA-N 0.000 description 1
- YBYPXSGVCBCUFL-UHFFFAOYSA-N tert-butyl 4-[3-(2-fluorophenyl)-2-oxoimidazolidin-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)N(C=2C(=CC=CC=2)F)CC1 YBYPXSGVCBCUFL-UHFFFAOYSA-N 0.000 description 1
- GNAKGSNPIDUYKO-UHFFFAOYSA-N tert-butyl 4-[5-methoxy-1-tri(propan-2-yl)silylpyrrolo[3,2-b]pyridin-6-yl]piperidine-1-carboxylate Chemical compound COC1=NC=2C=CN([Si](C(C)C)(C(C)C)C(C)C)C=2C=C1C1CCN(C(=O)OC(C)(C)C)CC1 GNAKGSNPIDUYKO-UHFFFAOYSA-N 0.000 description 1
- FLWASXZWXDVNNH-UHFFFAOYSA-N tert-butyl 4-[6-chloro-1-tri(propan-2-yl)silylpyrrolo[2,3-b]pyridin-4-yl]-4-hydroxypiperidine-1-carboxylate Chemical compound C1=C(Cl)N=C2N([Si](C(C)C)(C(C)C)C(C)C)C=CC2=C1C1(O)CCN(C(=O)OC(C)(C)C)CC1 FLWASXZWXDVNNH-UHFFFAOYSA-N 0.000 description 1
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- FODWRUPJCKASBN-UHFFFAOYSA-M tetrabutylazanium;chloride;hydrate Chemical compound O.[Cl-].CCCC[N+](CCCC)(CCCC)CCCC FODWRUPJCKASBN-UHFFFAOYSA-M 0.000 description 1
- RWWNQEOPUOCKGR-UHFFFAOYSA-N tetraethyltin Chemical compound CC[Sn](CC)(CC)CC RWWNQEOPUOCKGR-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79740006P | 2006-05-03 | 2006-05-03 | |
| US11/742,626 US7470680B2 (en) | 2006-05-03 | 2007-05-01 | Constrained compounds as CGRP-receptor antagonists |
| PCT/US2007/067998 WO2007131020A2 (en) | 2006-05-03 | 2007-05-02 | Constrained compounds as cgrp-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008013760A true MX2008013760A (es) | 2008-11-14 |
Family
ID=38544174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008013760A MX2008013760A (es) | 2006-05-03 | 2007-05-02 | Compuestos restringidos como antagonistas del receptor del peptido relacionado con el gen de calcitonica (cgrp). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7470680B2 (https=) |
| EP (1) | EP2013214B1 (https=) |
| JP (1) | JP2009535429A (https=) |
| KR (1) | KR20090018930A (https=) |
| AR (1) | AR060845A1 (https=) |
| AU (1) | AU2007248038A1 (https=) |
| BR (1) | BRPI0709759A2 (https=) |
| CA (1) | CA2651033A1 (https=) |
| IL (1) | IL195027A0 (https=) |
| MX (1) | MX2008013760A (https=) |
| NO (1) | NO20084564L (https=) |
| PE (1) | PE20080232A1 (https=) |
| TW (1) | TW200813063A (https=) |
| WO (1) | WO2007131020A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| EP2120564A4 (en) * | 2006-12-20 | 2011-05-04 | Merck Sharp & Dohme | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS |
| JP2011512410A (ja) * | 2008-02-19 | 2011-04-21 | メルク・シャープ・エンド・ドーム・コーポレイション | イミダゾベンゾアゼピンcgrp受容体アンタゴニスト |
| US8685969B2 (en) | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| WO2024220626A1 (en) * | 2023-04-20 | 2024-10-24 | Azkarra Therapeutics, Inc. | Small molecule modulators of ogg1 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205293B2 (en) | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| CA2518830A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| JP4705908B2 (ja) * | 2003-04-15 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Cgrp受容体拮抗薬 |
| JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| WO2005000807A2 (en) | 2003-06-26 | 2005-01-06 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| JP4705922B2 (ja) | 2004-01-29 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Cgrp受容体拮抗薬 |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| CA2582593A1 (en) | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Cgrp receptor antagonists |
| BRPI0517418A (pt) | 2004-10-13 | 2008-10-07 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça |
| AU2005295855B2 (en) | 2004-10-14 | 2011-08-18 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| AU2005299852B2 (en) | 2004-10-22 | 2011-08-04 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| CA2594940A1 (en) | 2005-01-18 | 2006-07-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
| CN101208303A (zh) | 2005-03-14 | 2008-06-25 | 默克公司 | Cgrp受体拮抗剂 |
| WO2007016087A2 (en) | 2005-07-29 | 2007-02-08 | Merck & Co., Inc. | Heterocyclic benzodiazepine cgrp receptor antagonists |
| EP2120564A4 (en) | 2006-12-20 | 2011-05-04 | Merck Sharp & Dohme | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS |
-
2007
- 2007-05-01 US US11/742,626 patent/US7470680B2/en active Active
- 2007-05-02 EP EP07761726.4A patent/EP2013214B1/en active Active
- 2007-05-02 KR KR1020087029499A patent/KR20090018930A/ko not_active Withdrawn
- 2007-05-02 MX MX2008013760A patent/MX2008013760A/es not_active Application Discontinuation
- 2007-05-02 JP JP2009510047A patent/JP2009535429A/ja active Pending
- 2007-05-02 AR ARP070101906A patent/AR060845A1/es not_active Application Discontinuation
- 2007-05-02 WO PCT/US2007/067998 patent/WO2007131020A2/en not_active Ceased
- 2007-05-02 AU AU2007248038A patent/AU2007248038A1/en not_active Abandoned
- 2007-05-02 PE PE2007000536A patent/PE20080232A1/es not_active Application Discontinuation
- 2007-05-02 CA CA002651033A patent/CA2651033A1/en not_active Abandoned
- 2007-05-02 BR BRPI0709759-0A patent/BRPI0709759A2/pt not_active IP Right Cessation
- 2007-05-03 TW TW096115732A patent/TW200813063A/zh unknown
-
2008
- 2008-10-30 IL IL195027A patent/IL195027A0/en unknown
- 2008-10-30 NO NO20084564A patent/NO20084564L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090018930A (ko) | 2009-02-24 |
| WO2007131020A2 (en) | 2007-11-15 |
| US7470680B2 (en) | 2008-12-30 |
| CA2651033A1 (en) | 2007-11-15 |
| EP2013214A2 (en) | 2009-01-14 |
| JP2009535429A (ja) | 2009-10-01 |
| AR060845A1 (es) | 2008-07-16 |
| TW200813063A (en) | 2008-03-16 |
| AU2007248038A1 (en) | 2007-11-15 |
| WO2007131020A3 (en) | 2008-01-17 |
| BRPI0709759A2 (pt) | 2011-10-25 |
| US20070259851A1 (en) | 2007-11-08 |
| PE20080232A1 (es) | 2008-04-11 |
| IL195027A0 (en) | 2009-08-03 |
| NO20084564L (no) | 2008-12-02 |
| EP2013214B1 (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7544680B2 (en) | Constrained compounds as CGRP-receptor antagonists | |
| JP6258537B2 (ja) | Cgrp受容体アンタゴニスト | |
| EP1945222B1 (en) | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | |
| WO2007130860A2 (en) | Constrained compounds as cgrp-receptor antagonists | |
| CA2583536A1 (en) | Cgrp receptor antagonists | |
| EP3480198A1 (en) | Novel compound or pharmaceutically acceptable salt thereof | |
| WO2012022707A1 (en) | Substituted heteroaryl spiropyrrolidine mdm2 antagonists | |
| AU2007314338A1 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | |
| EP2013214B1 (en) | Constrained compounds as cgrp-receptor antagonists | |
| CN101495480B (zh) | 作为降钙素基因相关肽受体拮抗剂的受限化合物 | |
| EP2013213B1 (en) | Constrained compounds as cgrp-receptor antagonists | |
| US20090054440A1 (en) | Quinoline derivatives as neurokinin receptor antagonists | |
| CN101094854A (zh) | 作为cgrp受体拮抗剂的受限化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |